PhotonMD Inc announces the addition of a top executive from the dermatology industry to the company’s leadership team. 

Brian Johnson has joined the company as president of the REVIAN business unit and will lead the commercialization efforts including sales, marketing, and professional relations for the company’s aesthetic products based on medical-grade LED light technology.

REVIAN’s product pipeline includes recently launched REVIAN RED, an all-LED wearable cap for the treatment of androgenetic alopecia (“pattern hair loss”). In a randomized, double-blind, placebo-controlled trial of REVIAN RED, 10-minute once-daily treatment successfully demonstrated the ability to stop hair loss and grow new hair.

Full clinical trial results are expected to be published in a peer-reviewed medical journal early next year. This treatment provides an effective alternative to topical agents and oral prescription drugs, a news release from the company explains.

“With all of the advancements in medicine, androgenetic alopecia shouldn’t be a skin disease that patients just have to ‘live with.’ We fundamentally believe that light can be used to put an end to hair loss,” Johnson states. 

Johnson brings 3 decades of sales and marketing leadership in companies ranging in size from large pharma companies like Novartis to microcap Novan Inc.

The majority of his commercial dermatology experience included roles at Johnson & Johnson, Medicis Pharmaceutical Corporation and Galderma Laboratories LLC, where he served as vice president of prescription marketing and chief digital officer.

“For some men and women living with hair loss, the impact on their quality of life and well-being can be devastating,” he continues.

“Dermatology healthcare providers and other professionals spend more time with this condition than anyone, so our strategy will be to utilize those existing relationships to integrate REVIAN RED into routine care. Compliance is an important component of the treatment regimen, and our mobile app was designed to help users stay on schedule.

“This cloud-based platform technology also provides us some unique opportunities in the future as we aim to make this device mainstream for the 70 to 80 million sufferers throughout the United States,” Johnson concludes.

[Source: PhotonMD Inc]